Wockhardt's Zaynich™ Enables US Cancer Patient to Undergo Successful Liver Transplant
In a recent case at Houston Methodist Hospital, Texas, Zaynich™ (Zidebactam/Cefepime, WCK 5222) successfully cleared a chronic bile duct infection in a 73-year-old female patient with bile duct cancer. The patient had developed sepsis and liver abscess due to extensively drug resistant Pseudomonas aeruginosa and Klebsiella pneumoniae, which were found to possess challenging resistance mechanisms. After failing to respond to several broad-spectrum antibiotics for over six weeks, the patient was treated with Zaynich™ for 15 days, which helped control the infectious processes and cleared the way for a liver transplant. Zaynich™ is a novel proprietary antibiotic by Wockhardt, nearing completion of Phase III studies, and has benefitted 45 patients under compassionate use.
Key Highlights
- Zaynich™ successfully cleared a chronic bile duct infection in a US cancer patient.
- The patient was suffering from extensively drug resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
- Zaynich™ treated the patient for 15 days, controlling infectious processes and facilitating a liver transplant.
- Zaynich™ is a novel proprietary antibiotic by Wockhardt, nearing completion of Phase III studies.
- 45 patients have benefitted from Zaynich™ under compassionate use.